Ahren Innovation Capital has led a $16m initial series A tranche for Mogrify, co-founded by researchers from Bristol, Monash and Duke universities.
Mogrify, a UK-based cell conversion technology developer with links to Bristol, Monash and Duke universities, today raised a $16m first series A tranche led by patient capital fund Ahren Innovation Capital.
Parkwalk Advisors, the fund management subsidiary of commercialisation firm IP Group, contributed to the round both directly and through its University of Bristol Enterprise Fund III. Private equity firm 24Haymarket also took part.
Incorporated in 2016, Mogrify is working on direct cellular conversion technology that enables any mature human cell type to be transformed into any other without the need for pluripotent stem cells.
The platform relies on big data analytics to identify the optimal parameters needed for conversion. Mogrify expects to develop cell therapies for musculoskeletal, auto-immune, ocular and respiratory diseases as well as for cancer immunotherapy.
Mogrify was co-founded by Julian Gough, honorary professor at University of Bristol, Jose Polo, professor of biochemistry…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
